Lb Pharmaceuticals (LBRX) Income towards Parent Company (2024 - 2026)

Lb Pharmaceuticals' Income towards Parent Company history runs 3 years deep, the most recent figure standing at -$19.1 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 259.1% year-over-year to -$19.1 million; the TTM figure through Mar 2026 stood at -$39.4 million (changed N/A YoY), while the FY2025 annual figure was -$25.2 million, up 60.06% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$19.1 million, down from -$11.5 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$3.6 million in Q3 2025, with the low at -$19.1 million in Q1 2026.
• The 3-year median for Income towards Parent Company is -$8.4 million (2025), against an average of -$9.8 million.
• The sharpest annual moves came in 2025 and 2026: Income towards Parent Company soared 74.92% in 2025, then sank 259.1% in 2026.
• Lb Pharmaceuticals' Income towards Parent Company stood at -$5.1 million in 2024, then tumbled by 126.23% to -$11.5 million in 2025, then slumped by 66.09% to -$19.1 million in 2026.
• Business Quant data shows LBRX's Income towards Parent Company at -$19.1 million in Q1 2026, -$11.5 million in Q4 2025, and -$3.6 million in Q3 2025.